Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		199 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Revenue	$ 0	$ 0	$ 0
Operating expenses:
Research and development	178	296	69,346
Gain on deferred lease inducements	0	0	386
Impairment of capital assets	0	0	(497)
Acquired in-process research and development	0	0	13,094
General and administrative	359	320	32,453
Loss from operations	(537)	(616)	(114,782)
Other income (expense):
Settlement of Cadherin Biomedical Inc. litigation	0	0	(1,283)
Interest expense	0	0	(19)
Unrealized/realized gain/(loss) on derivatives	(3,573)	3,327	(316)
Other income / (expense)	0	(4)	259
Interest income and other	2	8	2,899
Total other income, net	(3,571)	3,331	1,540
Net (loss) / income and comprehensive (loss) / income	$ (4,108)	$ 2,715	$ (113,242)
Basic and diluted net (loss) income per common share (In dollars per share)	$ (0.16)	$ 0.11
Weighted-average number of common shares outstanding, basic (In shares)	25,158	25,158
Weighted-average number of common shares outstanding, diluted (In shares)	25,158	25,158